Squalene synthase catalyzes the biosynthesis of squalene, a key cholesterol
precursor, through a reductive dimerization of two farnesyl diphosphate (F
PP) molecules. The reaction is unique when compared with those of other FPP
-utilizing enzymes and proceeds in two distinct steps, both of which involv
e the formation of carbocationic reaction intermediates. Because FPP is loc
ated at the final branch point in the isoprenoid biosynthesis pathway, its
conversion to squalene through the action of squalene synthase represents t
he first committed step in the formation of cholesterol, making it an attra
ctive target for therapeutic intervention. We have determined, for the firs
t time, the crystal structures of recombinant human squalene synthase compl
exed with several different inhibitors. The structure shows that SQS is fol
ded as a single domain, with a large channel in the middle of one face. The
active sites of the two half-reactions catalyzed by the enzyme are located
in the central channel, which is Lined on both sides by conserved aspartat
e and arginine residues, which are known from mutagenesis experiments to be
involved in FPP binding. One end of this channel is exposed to solvent, wh
ereas the other end leads to a completely enclosed pocket surrounded by con
served hydrophobic residues. These observations, along with mutagenesis dat
a identifying residues that affect substrate binding and activity, suggest
that two molecules of FPP bind at one end of the channel, where the active
center of the first half-reaction is located, and then the stable reaction
intermediate moves into the deep pocket, where it is sequestered from solve
nt and the second half-reaction occurs. Five alpha helices surrounding the
active center are structurally homologous to the active core in the three o
ther isoprenoid biosynthetic enzymes whose crystal structures are known, ev
en though there is no detectable sequence homology.